1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Cornerstone Therapeutics Inc. - Product Pipeline Review - 2013

Cornerstone Therapeutics Inc. - Product Pipeline Review - 2013

  • June 2013
  • -
  • Global Markets Direct
  • -
  • 33 pages

Cornerstone Therapeutics Inc. - Product Pipeline Review - 2013


Summary


Global Market Direct’s pharmaceuticals report, “Cornerstone Therapeutics Inc. - Product Pipeline Review - 2013” provides data on the Cornerstone Therapeutics Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Cornerstone Therapeutics Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Cornerstone Therapeutics Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.


Scope


- Cornerstone Therapeutics Inc. - Brief Cornerstone Therapeutics Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Cornerstone Therapeutics Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Cornerstone Therapeutics Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Cornerstone Therapeutics Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.


Reasons to buy


- Evaluate Cornerstone Therapeutics Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Cornerstone Therapeutics Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Cornerstone Therapeutics Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Cornerstone Therapeutics Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Cornerstone Therapeutics Inc. and identify potential opportunities in those areas.

Table Of Contents

Cornerstone Therapeutics Inc. - Product Pipeline Review - 2013
Table of Contents 2
List of Tables 3
List of Figures 3
Cornerstone Therapeutics Inc. Snapshot 4
Cornerstone Therapeutics Inc. Overview 4
Key Information 4
Key Facts 4
Cornerstone Therapeutics Inc. - Research and Development Overview 5
Key Therapeutic Areas 5
Cornerstone Therapeutics Inc. - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Out-Licensed Products/Combination Treatment Modalities 9
Cornerstone Therapeutics Inc. - Pipeline Products Glance 10
Cornerstone Therapeutics Inc. - Late Stage Pipeline 10
Registration Filed Products/Combination Treatment Modalities 10
Cornerstone Therapeutics Inc. - Early Stage Pipeline Products 11
Pre-Clinical Products/Combination Treatment Modalities 11
Cornerstone Therapeutics Inc. - Drug Profiles 12
CRTX-809 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
HMGB1 Monoclonal Antibody 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
lixivaptan 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
zileuton 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
Cornerstone Therapeutics Inc. - Pipeline Analysis 19
Cornerstone Therapeutics Inc. - Pipeline Products by Therapeutic Class 19
Cornerstone Therapeutics Inc. - Pipeline Products by Route of Administration 20
Cornerstone Therapeutics Inc. - Pipeline Products By Mechanism of Action 21
Cornerstone Therapeutics Inc. - Recent Pipeline Updates 22
Cornerstone Therapeutics Inc. - Dormant Projects 25
Cornerstone Therapeutics Inc. - Discontinued Pipeline Products 26
Discontinued Pipeline Product Profiles 26
CTI-01 26
Cornerstone Therapeutics Inc. - Company Statement 27
Cornerstone Therapeutics Inc. - Locations And Subsidiaries 30
Head Office 30
Other Locations and Subsidiaries 30
Appendix 32
Methodology 32
Coverage 32
Secondary Research 32
Primary Research 32
Expert Panel Validation 32
Contact Us 33
Disclaimer 33

List of Tables


Cornerstone Therapeutics Inc., Key Information 4
Cornerstone Therapeutics Inc., Key Facts 4
Cornerstone Therapeutics Inc. - Pipeline by Indication, 2013 6
Cornerstone Therapeutics Inc. - Pipeline by Stage of Development, 2013 7
Cornerstone Therapeutics Inc. - Monotherapy Products in Pipeline, 2013 8
Cornerstone Therapeutics Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2013 9
Cornerstone Therapeutics Inc. - Filed, 2013 10
Cornerstone Therapeutics Inc. - Pre-Clinical, 2013 11
Cornerstone Therapeutics Inc. - Pipeline By Therapeutic Class, 2013 19
Cornerstone Therapeutics Inc. - Pipeline By Route of Administration, 2013 20
Cornerstone Therapeutics Inc. - Pipeline Products By Mechanism of Action, 2013 21
Cornerstone Therapeutics Inc. - Recent Pipeline Updates, 2013 22
Cornerstone Therapeutics Inc. - Dormant Developmental Projects,2013 25
Cornerstone Therapeutics Inc. - Discontinued Pipeline Products, 2013 26
Cornerstone Therapeutics Inc., Subsidiaries 30

List of Figures


Cornerstone Therapeutics Inc. - Pipeline by Indication, 2013 6
Cornerstone Therapeutics Inc. - Pipeline by Stage of Development, 2013 7
Cornerstone Therapeutics Inc. - Monotherapy Products in Pipeline, 2013 8
Cornerstone Therapeutics Inc. - Pipeline By Therapeutic Class, 2013 19
Cornerstone Therapeutics Inc. - Pipeline By Route of Administration, 2013 20
Cornerstone Therapeutics Inc. - Pipeline Products By Mechanism of Action, 2013 21

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Me ...

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016’, provides in depth analysis ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.